Antineutrophil cytoplasmic antibodies reacting with the pro form of proteinase 3 and disease activity in patients with Wegener's granulomatosis and microscopic polyangiitis
- PMID: 11229478
- DOI: 10.1002/1529-0131(200102)44:2<463::AID-ANR65>3.0.CO;2-9
Antineutrophil cytoplasmic antibodies reacting with the pro form of proteinase 3 and disease activity in patients with Wegener's granulomatosis and microscopic polyangiitis
Abstract
Objective: Antineutrophil cytoplasmic antibodies (ANCA) directed against proteinase 3 (PR3) are diagnostic markers for the small vessel vasculitides Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA). Correlation of disease activity with PR3 ANCA levels, as determined by standard methods, is not apparent in every patient. PR3 ANCA react with yet to be identified conformational epitopes. We have identified PR3 ANCA subsets that react differentially with mature recombinant PR3 (rPR3; lacking the N-terminal activation dipeptide) and the pro form of this enzyme (pro-rPR3). The present study was performed to determine the association of these PR3 ANCA subsets with disease activity.
Methods: Sera from 61 PR3 ANCA-positive patients with WG or MPA were assayed by capture enzyme-linked immunosorbent assay using pro-rPR3 and rPR3 as target antigens, and were correlated with disease activity as determined by the Birmingham Vasculitis Activity Score (BVAS).
Results: Median levels of PR3 ANCA reacting with pro-rPR3 were higher during active (n = 32) than during inactive (n = 29) disease (P = 0.016). Reactivity with mature rPR3 was not significantly different (P = 0.71). Serial followup in individual patients also indicated better correlation of PR3 ANCA reactivity with pro-rPR3 than with mature rPR3.
Conclusion: PR3 ANCA subsets reactive with epitopes accessible on pro-PR3 correlate better with disease activity than do subsets reactive with epitopes accessible only on mature PR3. This observation may explain why ANCA levels determined with current standard methods are suboptimal for monitoring disease activity. It raises new questions about the primary target of the PR3 ANCA immune response in patients with small vessel vasculitis.
Comment in
-
Clinical and prognostic value of antineutrophil cytoplasmic antibodies in Wegener's granulomatosis and microscopic polyangiitis: comment on the article by Russell et al.Arthritis Rheum. 2002 Jan;46(1):278-80. doi: 10.1002/1529-0131(200201)46:1<278::AID-ART10077>3.0.CO;2-U. Arthritis Rheum. 2002. PMID: 11817605 No abstract available.
-
Pro-myeloperoxidase, a target antigen for antineutrophil cytoplasm autoantibodies: comment on the article by Russell et al.Arthritis Rheum. 2002 Apr;46(4):1127-9. doi: 10.1002/art.10145. Arthritis Rheum. 2002. PMID: 11953997 No abstract available.
Similar articles
-
IgG from myeloperoxidase-antineutrophil cytoplasmic antibody-positive patients stimulates greater activation of primed neutrophils than IgG from proteinase 3-antineutrophil cytosplasmic antibody-positive patients.Arthritis Rheum. 2001 Apr;44(4):921-30. doi: 10.1002/1529-0131(200104)44:4<921::AID-ANR149>3.0.CO;2-4. Arthritis Rheum. 2001. PMID: 11315931
-
A study of conformational restraints on reactivity of human PR3-specific autoantibodies (ANCA) facilitated through protein folding manipulations of a new recombinant proteinase 3 protein.Autoimmunity. 2007 Nov;40(7):503-11. doi: 10.1080/08916930701680104. Autoimmunity. 2007. PMID: 17966040
-
A novel capture-ELISA for detection of anti-neutrophil cytoplasmic antibodies (ANCA) based on c-myc peptide recognition in carboxy-terminally tagged recombinant neutrophil serine proteases.J Immunol Methods. 2005 Dec 20;307(1-2):62-72. doi: 10.1016/j.jim.2005.09.004. Epub 2005 Oct 3. J Immunol Methods. 2005. PMID: 16242707
-
Pathogenesis of PR3-ANCA associated vasculitis.J Autoimmun. 2008 Feb-Mar;30(1-2):29-36. doi: 10.1016/j.jaut.2007.11.005. Epub 2007 Dec 26. J Autoimmun. 2008. PMID: 18162369 Review.
-
'Classic' anti-neutrophil cytoplasmic autoantibodies (cANCA), 'Wegener's autoantigen' and their immunopathogenic role in Wegener's granulomatosis.J Autoimmun. 1993 Apr;6(2):171-84. doi: 10.1006/jaut.1993.1015. J Autoimmun. 1993. PMID: 8388690 Review.
Cited by
-
Evaluation of PR3-ANCA Status After Rituximab for ANCA-Associated Vasculitis.J Clin Rheumatol. 2019 Aug;25(5):217-223. doi: 10.1097/RHU.0000000000001030. J Clin Rheumatol. 2019. PMID: 30896460 Free PMC article.
-
Neutrophil surface presentation of the anti-neutrophil cytoplasmic antibody-antigen proteinase 3 depends on N-terminal processing.Clin Exp Immunol. 2008 Jun;152(3):508-16. doi: 10.1111/j.1365-2249.2008.03663.x. Clin Exp Immunol. 2008. PMID: 18462208 Free PMC article.
-
A painful diagnosis.Intern Emerg Med. 2017 Apr;12(3):341-347. doi: 10.1007/s11739-017-1638-4. Epub 2017 Feb 25. Intern Emerg Med. 2017. PMID: 28238180 No abstract available.
-
Two Decades Rituximab Therapy in Anti-Neutrophil Cytoplasmic Antibody Associated Vasculitis.Curr Drug Targets. 2025;26(2):73-87. doi: 10.2174/0113894501323529240910015912. Curr Drug Targets. 2025. PMID: 39318005 Review.
-
Epitope Spreading in Immune-Mediated Glomerulonephritis: The Expanding Target.Int J Mol Sci. 2024 Oct 16;25(20):11096. doi: 10.3390/ijms252011096. Int J Mol Sci. 2024. PMID: 39456878 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical